ampliphi biosciences

p25162 • Mar 10, 2014 9:44 PM

   3 users liked this posts users disliked this posts 0
   Reply

$20 Billion addressable market for Ampliphi's initial 3 Phage programs - NYSE listing soon

Impressive presentation by CEO Phil Young today at the 26th Annual ROTH Conference. It was well received by institutional investors/analysts. I recommend listening and viewing the webcast presentation link at their website. "2014 transformational year: multiple valuation driving milestones."

Agreed - NYSE listing coming up before 30th June it seems, plus lots of further news flow this year per slides 23 and 12, with:

P001 - phase 1/2a study initiated in H2'14 with data in H1'15
P002 - initiate phase 1 study in H2'14
P004 - non-clinical proof of date in H2'14

amongst others:

wsw.com/webcast/roth28/aphb/

p25162 • 20 hours ago

   1 users liked this posts users disliked this posts 0
   Reply

RA Capital Management ($850 mil. fund)- loaded up on APHB - recent 13G filing

RA Capital Management, LLC – 26,785,712 shares = 9.9% ownership
Peter Kolchinsky – 26,785,712 shares = 9.9% ownership
RA Capital Healthcare Fund, L.P. – 21,428,575 shares = 7.9% ownership

RA Capital manages approximately $850 mil. The clearly like what they see with Ampliphi. I especially like the fact that Peter K. took a personal (individual) stake as well in Ampliphi with a 9.9% stake.

Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment became $13 Million. Boston-based RA Capital invests in companies with promising drugs and technologies.

   ce259 • Apr 5, 2014 12:32 AM
       0 users liked this posts users disliked this posts 0
       Reply
   10-K

   The Company intends to file the 2013 10-K by April 15, 2014,
   Hopefully this will start the upward trend toward $1

This is one of the challenges from transitioning to SEC full reporting (disclosure) company and moving to the NYSE. Bottom line APHB's audit team caught the complex Derivatives and Hedging issue dealing with estimated fair value of the derivative instruments that should be recorded as non-cash income or expense in the statement of operations.

Most important point, the non-cash adjustments to the financial statements as of September 30, 2013, do not impact the amounts previously reported for the Company's cash and cash equivalents, operating expenses, or total operating, investing or financing cash flows. No material impact.

Billionaire, CEO of Intrexon Randal Kirk, SEC 13G filing (2-14-15) owns 67.6% of APHB

Randal Kirk (CEO of Intrexon) has a track record of significant investment returns for himself and investors that follow. Based on last weeks 13G filing, Mr. Kirk, Third Security, NRM VII Holdings and Intrexon (all controlled by Kirk), own 67.6% of AmpliPhi. Randal didn't buy all these APHB shares as a tax write off.

e.g. Randal recently purchased an additionally 555k Intrexon (XON) shares in a secondary at $27. Stock closed at $39.30, equating to approx. $7 mil. return in less a month. Plus he already owned 61 mil. shares of Intrexon.

Gestern wieder 2.600.000 stk. Irgendwas läuft da?!

It looks like we are a few short days or weeks from the beginning of a very interesting timeline for shareholders.

AmpliPhage-002: S. aureus (MRSA)
• IND Enabling Preclinical Studies Q2 2015
• cGMP Product Release Q2 2015
• IND Filing Q3 2015
• Phase 1 Clinical Study FPFV Q4 2015
AmpliPhage-001: P. aeruginosa Cystic Fibrosis
• Product qualification Q2 2015
• cGMP Product Manufacturing Q3 2015
• Nebulizer Qualification Q4 2015
• Inhalation Toxicology Q4 2015
AmpliPhage-004: C. difficile(CDI/ CDAD)
• Preclinical efficacy data Q2 2015
• Product qualification Q4 2015

Next 90 days

Events in the next 90 days;
IND Enabling Preclinical Studies for MRSA and cGMP Product Release
Cystic Fibrosis product qualification
C. difficile (CDI/ CDAD) preclinical efficacy data

hoch bei 0,30$

Bis jetzt!!

war nicht normal! bin in der Aktie schon lange drinn, war immer sehr volatil. otc halt. aber so wie gestern war schon lange nicht.

mfg  

toegar2000 yahoo



AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections!!!
This should rocket upward big time today! Good luck longs.

@

OTC Markets Group Congratulates AmpliPhi Biosciences on NYSE MKT Listing